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Abstract
The aim of this study was to further characterize pharmacological properties of two phenyl-
piperazine derivatives: 1-{2-[2-(2,6-dimethlphenoxy)ethoxy]ethyl}-4-(2-methoxyphenyl)
piperazynine hydrochloride (HBK-14) and 2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl-4-
(2- methoxyphenyl)piperazynine dihydrochloride (HBK-15) in radioligand binding and func-
tional in vitro assays as well as in vivomodels. Antidepressant-like properties were investi-
gated in the forced swim test (FST) in mice and rats. Anxiolytic-like activity was evaluated in
the four-plate test in mice and elevated plus maze test (EPM) in rats. Imipramine and escita-
lopram were used as reference drugs in the FST, and diazepam was used as a standard
anxiolytic drug in animal models of anxiety. Our results indicate that HBK-14 and HBK-15
possess high or moderate affinity for serotonergic 5-HT2, adrenergic α1, and dopaminergic
D2 receptors as well as being full 5-HT1A and 5-HT7 receptor antagonists. We also present
their potent antidepressant-like activity (HBK-14—FST mice: 2.5 and 5 mg/kg; FST rats:
5 mg/kg) and (HBK-15—FST mice: 1.25, 2.5 and 5 mg/kg; FST rats: 1.25 and 2.5 mg/kg).
We show that HBK-14 (four-plate test: 2.5 and 5 mg/kg; EPM: 2.5 mg/kg) and HBK-15 (four-
plate test: 2.5 and 5 mg/kg; EPM: 5 mg/kg) possess anxiolytic-like properties. Among the
two, HBK-15 has stronger antidepressant-like properties, and HBK-14 displays greater
anxiolytic-like activity. Lastly, we demonstrate the involvement of serotonergic system, par-
ticularly 5-HT1A receptor, in the antidepressant- and anxiolytic-like actions of investigated
compounds.
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Introduction
Depression is a very serious mood disorder, characterized by low mood, anhedonia, reduced
energy, and often comorbid with anxiety. Its unclear aetiology may involve genetic factors,
abnormal neurotransmission in the central nervous system (CNS), neuroendocrine or immu-
nological processes. Patients suffering from depressive disorders have impaired serotonergic
5-HT1A receptor function [1–3]. Post-mortem studies demonstrated some alterations in ago-
nist-stimulated 5-HT1A receptor activation in depressed suicide victims [4]. Furthermore, a C
(-1019)G (rs6295) promoter polymorphism of the 5-HT1A receptor gene (HTR1A) has been
identified and has been proven to increase the risk of affective disorders and the resistance to
selective serotonin reuptake inhibitors (SSRIs) treatment [5]. Serotonergic 5-HT1A receptors
were found in many brain regions, including limbic structures and cerebral cortex, and are
involved in many physiological and pathological processes [6]. It is not surprising though that
many studies on 5-HT1A receptor ligands with the possible use in the treatment of mood disor-
ders are still being performed. Some of 5-HT1A receptor ligands are already used in the therapy
of depression, e.g. vilazodone and vortioxetine (serotonin reuptake inhibitors and partial
5-HT1A agonists) or generalized anxiety disorder–buspirone (a partial 5-HT1A receptor ago-
nist) [7,8]. 5-HT1A antagonists haven’t been introduced to the treatment of depression so far
but they may have beneficial effects i.e. accelerating/enhancing the clinical effects of SSRIs [9].
This could be achieved by preventing 5-HT1A- autoreceptor-mediated negative feedback. Pin-
dolol, a non-selective β-adrenoceptor and 5-HT1A receptor antagonist, enhanced the efficacy
of SSRIs in depressed patients [10]; however, its effect on cardio-vascular system limits its clini-
cal use. Another compound DU-125530—a potent pre- and postsynaptic 5-HT1A receptor
antagonist—augmented SSRI-induced increases in extracellular 5-HT but did not accelerate
the effects of fluoxetine in depressed individuals [11]. The authors suggested that the blockade
of postsynaptic 5-HT1A receptors canceled the benefits of enhancing presynaptic 5-hydroxy-
tryptaminergic function. Therefore, we should search for selective presynaptic 5-HT1A antago-
nists or multimodal compounds with weak 5-HT1A antagonistic properties.
Analogously, there is evidence that 5-HT7 receptors play an important role in affective dis-
orders [12,13]. Although the detailed analysis of 5-HT7 receptor distribution in individuals
with depression or anxiety is not available yet, recent animal studies showed up-regulation of
5-HT7 receptors in the hippocampus after exposure to stress [14,15], and these adaptive
changes were inhibited by fluoxetine [14,15]. Interestingly, 5-HT7 knockout mice exhibit a
behavioural phenotype similar to mice treated with antidepressants [16,17]. Moreover, a selec-
tive 5-HT7 receptor antagonist SB 269970 produced antidepressant- and anxiolytic-like effects
in behavioural animal models. It is also worth mentioning that vortioxetine is a 5-HT7 receptor
antagonist.
Literature data indicate that phenylpiperazine derivatives present various potential thera-
peutic properties, including analgesic, antipsychotic, antidepressant and/or anxiolytic detected
in animal models, thus this group of compounds has been widely studied by many researchers
[18–25].
In the present study antidepressant- and anxiolytic-like activity, as well as a possible mecha-
nism of action of two 2-methoxyphenylpiperazine derivatives: 1-{2-[2-(2,6-dimethlphenoxy)
ethoxy]ethyl}-4-(2-methoxyphenyl)piperazynine hydrochloride (HBK-14) and 2-[2-(2-chloro-
6-methylphenoxy)ethoxy]ethyl-4-(2- methoxyphenyl)piperazynine dihydrochloride (HBK-15)
were evaluated in preclinical models sensitive to clinically effective antidepressants and anxio-
lytics in mice and rats. Since in our previous studies HBK-14 and HBK-15 showed high or
moderate affinity for 5-HT1A (Ki = 41 nM, Ki<1 nM, respectively) and 5-HT7 receptors (Ki =
156 nM, Ki = 34 nM, respectively), the aim of this study was to determine their intrinsic activity
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towards the above receptors as well as to broaden their affinity profile in vitro. As monoamin-
ergic receptors are known to play a pivotal role in antidepressant and anxiolytic activity, beha-
vioural studies were conducted to establish the potential of these compounds for such actions.
Methods
Animals
Experiments were performed on adult male mice (CD-1, 18–21 g) or male rats (Wistar, 170–
220 g), purchased from Animal Facility at the Faculty of Pharmacy, Jagiellonian University
Medical College, Krakow, Poland. Animals were kept in standard cages at room temperature of
22 ± 2°C under light/dark (12:12) cycle, and had free access to food (standard laboratory pel-
lets) and water before experiments. All experiments were performed between 9 a.m. and 2 p.m.
For all experiments animals were selected randomly. The animals were used only once in each
test. All injections were given in a volume of 10 ml/kg (mice) and 2 ml/kg (rats). Each experi-
mental group consisted of 10 (mice) or 8 (rats) animals. A trained observer blind to the treat-
ments scored behavioural experiments. All experimental procedures involving animals were
conducted in accordance with European Union and Polish legislation acts concerning animal
experimentation and approved by the I Local Ethics Committee for Experiments on Animals
of the Jagiellonian University in Krakow, Poland (approval numbers: 74/2012, 7/2013, 52/2014
and 114/2015). All efforts were made to minimize suffering and to reduce the number of ani-
mals used in the experiments.
Drugs
Two studied phenylpiperazine derivatives shown in Fig 1: 1-{2-[2-(2,6-dimethlphenoxy)eth-
oxy]ethyl}-4-(2-methoxyphenyl)piperazynine hydrochloride (HBK-14) and 2-[2-(2-chloro-
6-methylphenoxy)ethoxy]ethyl-4-(2- methoxyphenyl)piperazynine dihydrochloride (HBK-15)
were synthesized in the Department of Bioorganic Chemistry, Chair of Organic Chemistry,
Pharmacy Faculty, Jagiellonian University, Krakow, Poland [26]. HBK-14, HBK-15, diazepam
(Tocris, United Kingdom), imipramine (Sigma-Aldrich, Germany), escitalopram (Lundbeck,
Denmark), fluoxetine (Sigma-Aldrich, Germany), reboxetine (Sigma-Aldrich, Germany), and
bupropion (Sigma-Aldrich, Germany) were dissolved in saline and administered intraperitone-
ally (i.p.) 30 min before each test. p-Chlorophenylalanine (pCPA) was suspended in 1% Tween
80 solution and administered i.p. for 3 consecutive days. N-{2-[4-(2-metho xyphenyl)-1-piper-
azinyl] ethyl}- N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) was
dissolved in saline and injected subcutaneously, 15 min before the studied compounds. The
control groups received 0.9% NaCl (i.p.). For radioligand and functional experiments mian-
serin (Sigma-Aldrich, Germany), escitalopram (Lundbeck, Denmark), phentolamine (Sigma-
Aldrich, Germany), clonidine (Sigma-Aldrich, Germany), propranolol (Sigma-Aldrich, Ger-
many), haloperidol (Sigma-Aldrich, Germany), serotonin (Sigma-Aldrich, Germany), and SB
269970 (Tocris, United Kingdom) were dissolved in dimethyl sulfoxide (DMSO) and used as
reference compounds.
Radioligand binding assays
Serotonergic 5-HT2A receptor. Radioligand binding was performed using membranes
from CHO-K1 cells stably transfected with the human 5-HT2A receptor. Monolayer of
CHO-K1 cells with stable expression of human receptor after reaching about 90% confluence
was washed twice with PBS. After that the cells were scrapped and collected to centrifuge tubes.
About 20 volumes of assay buffer was added to each tube and cells were homogenized (3 x 10
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sec., 24 000 rpm; Ultra Turrax T25B homogenizator, IKA Labortechnik, USA). Tubes were
centrifuged (20 min., 30 000 x g, about 4°C; 3K30 centrifuge, Sigma Laborzentrifugen, Ger-
many). Supernatant was discarded and appropriate volume of assay buffer with 10% glycerol
was added and homogenization was repeated. Membrane suspension was aliquoted into cryo-
tubes, freezed in liquid nitrogen and stored until assay in -80°C. Membrane protein concentra-
tion was determined by BCA method. Immediately before assay frozen membranes were
thawed quickly (about 35°C), mixed and homogenized (60 sec., 24,000 rpm) with appropriate
volume of assay buffer to reach desired membrane protein concentration. All assays were car-
ried out in duplicates. Determination of the equilibrium dissociation constant (KD) was con-
ducted by saturation experiments with increasing series of concentrations of a [3H]-ketanserin
(0.05–3.0 nM). 50 μl working solution of the tested compounds, 50 μl [3H]-ketanserin (final
concentration 0,5 nM, KD 0.3 nM) and 150 μl diluted membranes (5 μg protein per well) pre-
pared in assay buffer (50 mM Tris, pH 7.4, 4 mM CaCl2, 0.1% ascorbic acid) were transferred
to polypropylene 96-well microplate using 96-wells pipetting station Rainin Liquidator (Met-
tlerToledo). Serotonin (100 μM) was used to define nonspecific binding. Microplate was cov-
ered with a sealing tape, mixed and incubated for 60 minutes at 27°C. The reaction was
terminated by rapid filtration through GF/B filter mate presoaked with 0.3% polyethyleneimine
for 30 minutes. Ten rapid washes with 200 μl 50 mM Tris buffer (4°C, pH 7.4) were performed
using automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates
were dried at 37°C in forced air fan incubator and then solid scintillator MeltiLex was melted
on filter mates at 90°C for 5 minutes. Radioactivity was counted in MicroBeta2 scintillation
counter (PerkinElmer) at approximately 30% efficiency. Inhibition constants (Ki) were
calculated.
Fig 1. Chemical structures of HBK-14 and HBK-15. (A) 1-{2-[2-(2,6-dimethlphenoxy)ethoxy]ethyl}-4-(2-methoxyphenyl)piperazynine hydrochloride—
HBK-14, (B) 2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl-4-(2- methoxyphenyl)piperazynine dihydrochloride—HBK-15
doi:10.1371/journal.pone.0142499.g001
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Serotonin transporter (SERT). The experiment was performed according to the slightly
modified method described by Owens et al. [27]. Rat cerebral cortex was homogenized in 30
volumes of ice-cold 50 mM Tris-HCl containing 150 mMNaCl and 5 mM KCl, pH = 7.7 at
25°C and centrifuged at 20,000xg for 20 min. The supernatant was decanted and pellet was re-
suspended in 30 volumes of buffer and centrifuged again. The resulting pellet was re-suspended
in the same quantity of the buffer and centrifuged third time in the same conditions. [3H]-cita-
lopram (spec. act. 85,6 Ci/mmol, Perkin Elmer) was used for labelling 5-HT-transporter. 240 μl
of the tissue suspension, 30 μl of 1 μM imipramine (displacer), 30 μl of 1nM [3H]-citalopram
and 30 μl of the analysed compound were incubated at 24°C for 1 h. The concentrations of ana-
lysed compounds ranged from 10−10 to 10−5 M. The incubation was terminated by rapid filtra-
tion over glass fibre filters FilterMate B (PerkinElmer, USA) using 96-well FilterMate harvester
(PerkinElmer, USA). Ki values were calculated.
α1-, α2- and β1-adrenoceptors. The experiments were performed using rat cerebral cor-
tex. [3H]-prazosin (19.5 Ci/mmol, α1-adrenoceptor), [
3H]-clonidine (70.5 Ci/mmol, α2-adre-
noceptor) and [3H]-CGP-12177 (48 Ci/mmol, β1-adrenoceptor) were used. The membrane
preparation and the assay procedures were conducted according to the slightly modified
method described by Maj et al. [28]. Rat brains were homogenized in 20 volumes of ice-cold 50
mM Tris–HCl buffer (pH 7.6) and centrifuged at 20,000xg for 20 min (0–4°C). The cell pellet
was re-suspended in Tris–HCl buffer and centrifuged again. The final incubation mixture
(final volume 300 μL) consisted of 240 μL membrane suspension, 30 μL of a [3H]-prazosin (0.2
nM), [3H]-clonidine (2 nM) or [3H]-CGP-12177 (0.2 nM) solution and 30 μL buffer containing
from seven to eight concentrations (10−11–10−4 M) of investigated compounds. To measure
unspecific binding, phentolamine -10 μM (for [3H]-prazosin), 10 μM clonidine (for [3H]-cloni-
dine) and propranolol -1 μM (for [3H]-CGP-12177), were applied. Radioactivity was measured
in a WALLAC 1409 DSA liquid scintillation counter (Perkin Elmer, USA). All assays were
done in duplicates. Ki values were calculated.
Dopaminergic D2 receptor. Radioligand binding was performed using membranes from
CHO-K1 cells stably transfected with the human D2 receptor. All assays were carried out in
duplicates. KD for receptor radioligand was determined by saturation experiments with
increasing series of concentrations of [3H]-methylspiperon (0.05–3.0 nM). 50 μl working solu-
tion of the tested compounds, 50 μl [3H]-methylspiperon (final concentration 0.4 nM, KD 0.4
nM) and 150 μl diluted membranes (10 μg protein per well) prepared in assay buffer (50 mM
HEPES, pH 7.4, 50 mMNaCl, 5 mMMgCl2, 0.5 mM EDTA) were transferred to polypropylene
96-well microplate using 96-wells pipetting station Rainin Liquidator (MettlerToledo). (+)-
butaclamol (10 μM) was used to define nonspecific binding. Microplate was covered with a
sealing tape, mixed and incubated for 60 minutes at 37°C. The reaction was terminated by
rapid filtration through GF/C filter mate pre-soaked with 0.3% polyethyleneimine for 30 min-
utes. Ten rapid washes with 200 μl 50 mM Tris buffer (4°C, pH 7.4) were performed using
automated harvester system Harvester-96 MACH III FM (Tomtec). The filter mates were
dried at 37°C in forced air fan incubator and then solid scintillator MeltiLex was melted on fil-
ter mates at 90°C for 5 minutes. Radioactivity was counted in MicroBeta2 scintillation counter
(PerkinElmer) at approximately 30% efficiency. Ki values were calculated.
Functional assays
5-HT1A receptor. Test and reference compounds were dissolved in DMSO at a concentra-
tion of 1 mM. Serial dilutions were prepared in 96-well microplate in assay buffer and 8 to 10
concentrations were tested. A cellular aequorin-based functional assay was performed with
recombinant CHO-K1 cells expressing mitochondrially targeted aequorin, human GPCR and
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the promiscuous G protein α16 for 5-HT1A. Assay was executed according to previously
described protocol [29]. After thawing, cells were transferred to assay buffer (DMEM/HAM’s
F12 with 0.1% protease free BSA) and centrifuged. The cell pellet was resuspended in assay buffer
and coelenterazine h was added at final concentrations of 5 μM. The cells suspension was incu-
bated at 16°C, protected from light with constant agitation for 16 h and then diluted with assay
buffer to the concentration of 100,000 cells/ml. After 1 h of incubation, 50 μl of the cells suspen-
sion was dispensed using automatic injectors built into the radiometric and luminescence plate
counter MicroBeta2 LumiJET (PerkinElmer, USA) into white opaque 96-well microplates pre-
loaded with test compounds. Immediate light emission generated following calciummobilization
was recorded for 30 s. In antagonist mode, after 25 min of incubation the reference agonist was
added to the above assay mix and light emission was recorded again. Final concentration of the
reference agonist was equal to EC80 (100 nM serotonin). IC50 and EC50 values were calculated.
5-HT7 receptor. Test and reference compounds were dissolved in DMSO at a concentration
of 1 mM. Serial dilutions were prepared in 96-well microplate in assay buffer and 8 to 10 concen-
trations were tested. For the 5-HT7 receptor, adenylyl cyclase activity was monitored using cryo-
preserved CHO-K1 cells with expression of the human serotonin 5-HT7 receptor. Functional
assay based on cells with expression of the human 5-HT7 receptor was performed, according to
the previously described protocol [29]. CHO-K1 cells were transfected with a beta lactamase
(bla) reporter gene under control of the cyclic AMP response element (CRE) (Life Technologies).
Thawed cells were resuspended in stimulation buffer (HBSS, 5 mMHEPES, 0.5 IBMX, and
0.1% BSA at pH 7.4) at 2x105 cells/ml for 5-HT7 receptor. The same volume (10 μl) of cell sus-
pension was added to tested compounds for 5-HT7 receptor. Samples were loaded onto a white
opaque half area 96-well microplate. The antagonist response experiment was performed with
10 nM serotonin as the reference agonist for 5-HT7 receptor. The agonist and antagonist were
added simultaneously. Cell stimulation was performed for 1h at room temperature. After incu-
bation, cAMP measurements were performed with homogeneous TR-FRET immunoassay
using the LANCE Ultra cAMP kit (PerkinElmer, USA). 10 μl of EucAMP Tracer Working
Solution and 10 μl of ULight-anti-cAMP Tracer Working Solution were added, mixed, and
incubated for 1 h. The TR-FRET signal was read on an EnVision microplate reader (PerkinEl-
mer, USA). IC50 and EC50 values were calculated.
Forced swim test (FST) in mice
The studies were carried out on mice according to the method described by Porsolt et al. [30]. The
animals were dropped individually into glass cylinders (height 25 cm, diameter 10 cm) containing
10 cm of water, maintained at 23–25°C. Mice were left in the cylinder for 6 min. After the first 2
min of adaptation, the total duration of immobility was measured during the following 4-min test.
The mouse was judged to be immobile when it remained floating passively in the water.
Studied compounds and reference drugs were administered (i.p.) 30 min before the test.
The sub-effective doses of antidepressants (fluoxetine, reboxetine and bupropion) used in the
experiments were selected based on a dose-response curve described in our previous studies
[31]. To investigate the possible involvement of 5-HT1A receptors in antidepressant-like activ-
ity of studied compounds in the FST, mice were pretreated with WAY-100635 (0.1 mg/kg, s.c.)
15 min before the injection of HBK-14 or HBK-15, and after 30 min the FST was performed.
The dose of WAY-100635 used in the experiments was based on the literature data [32].
Locomotor activity in mice
Locomotor activity of mice was measured in photoresistor actometers (Ugo Basile, Italy) con-
nected to a counter for the recording of light-beam interruptions. Mice were placed
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individually in cages for 30 min and then the number of crossings of the light beams was
recorded as the locomotor activity between 2nd and 6th min or for 60 s (i.e. time equal to the
observation period in FST or the four-plate test, respectively). Studied compounds were admin-
istered (i.p.) 30 min before the test.
FST in rats
The experiment was carried out according to the method of Detke et al. [33]. On the first
experimental day rats were placed individually in Plexiglas cylinders (40 cm height, 18 cm in
diameter) containing 30 cm of water maintained at 25°C for 15 min. After that time the rats
were placed for 30 min under a 60-W bulb to dry. 24 hours after the pre-test, the rats were
placed again in the cylinders and the total duration of immobility (when a rat remained floating
in the water without struggling and was making only those movements necessary to keep its
head above water), swimming (when a rat was making active swimming motions, more than
necessary to merely maintain its head above water, e.g. moving around in the cylinder) and
climbing (when a rat was making active movements with its forepaws in and out of the water,
usually directed against the walls) was recorded during the whole 5-min test period. Fresh
water was used for each animal. Studied compounds and reference drugs were administered (i.
p.) 30 min before the test.
Serotonergic depletion
In order to examine the possible involvement of a serotonergic system to the effect of HBK-14 and
HBK-15 in the FST, the mice were pretreated with an inhibitor of tryptophan hydroxylase,
involved in the serotonin synthesis, i.e. pCPA, according to the method described by Pytka et al.
[31,34]. Once daily for 3 consecutive days the mice were injected i.p. with either pCPA at a dose of
200 mg/kg or 1% Tween 80 solution, depending on the group. On the test day, 24 h after the last
pCPA administration and 30 min before the FST, mice received HBK-14, HBK-15 or 0.9% NaCl.
Four-plate test in mice
The four-plate test was carried out according to the method described by Aron et al. [35]. The
box (BIOSEB, Vitrolles, France) was made of an opaque plastic and was rectangular (25 cm x
18 cm x 16 cm) in shape. The floor was covered with four rectangular metal plates (11 cm x 8
cm), separated by a 4 mm gap. The plates were connected to a source of continuous current,
which enabled a 120 V difference of potential between two adjacent plates for 0.5 s when the
experimenter pressed the switch. Mice were placed individually onto the plate, and were
allowed to explore for 15 s. Afterwards, each time a mouse passed from one plate to another,
the experimenter electrified the whole floor which evoked a visible flight reaction of the animal.
If the animal continued running, it received no new shocks for the following 3 s. The episodes
of punished crossings were counted for 60 s.
Studied compounds and reference drugs were administered (i.p.) 30 min before the test. To
investigate the possible involvement of 5-HT1A receptors in anxiolytic-like activity of studied
compounds in the four-plate test, mice were pretreated withWAY-100635 (0.1 mg/kg, s.c.)
15 min before the injection of HBK-14 or HBK-15, and after 30 min the four-plate test was per-
formed. The dose ofWAY-100635 used in the experiments was based on the literature data [32].
Elevated plus maze (EPM) test in rats
Plus-maze apparatus (an automated device produced by Campden Instruments Ltd, UK) made
of durable, high density, nonporous black plastic, elevated to a height of 50 cm, consisted of
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two open arms (50 cm x 10 cm) and two closed arms (50 cm x 10 cm, and 30 cm high walls),
arranged so that the two arms of each type were opposite each other. Floor of the plus-maze
was made of infrared transparent material what means that there are no visible sensors. The
plus-maze was placed in a darkened room; only the centre of the apparatus was illuminated
with low-density light (30 lux measured on the maze level). Plus-maze apparatus was con-
nected to PC software by control chassis. Each rat was gently placed in the centre of the plus-
maze, facing one of the closed arms, immediately after a 5-min adaptation period in a plastic
black box (60 cm x 60 cm x 35 cm). During a 5-min test period, automated Motor Monitor Sys-
tem recorded the number of entries into the closed and open arms, the time spent in either
type of the arms. After each trial the maze was wiped clean. Studied compounds and reference
drug were administered (i.p.) 30 min before the test.
Exploratory activity in rats
Exploratory activity in rats was measured using the EPM apparatus (described in section: Ele-
vated plus maze test in rats), connected to a computer equipped with a programMotor Moni-
tor System (Campden Instruments Ltd, UK). Each rat was gently placed in the centre of the
plus-maze, facing one of the closed arms, immediately after a 5-min adaptation period in a
plastic black box (60 cm x 60 cm x 35 cm). During a 5-min test period, the system recorded the
total number of entries into arms and the total distance travelled. After each trial the maze was
wiped clean. Studied compounds and reference drug were administered (i.p.) 30 min before
the test.
Data analysis
The data obtained were presented as mean ± S.E.M. and evaluated using one- or two-way anal-
ysis of variance (ANOVA), followed by Newman-Keuls or Bonferroni’s test post hoc, respec-
tively. Differences between groups were considered significant if P<0.05. In a case of
radioligand binding studies, the obtained data were fitted to a one-site curve-fitting equation
with Prism 6.0 (GraphPad Software), and Ki values were estimated from the Cheng−Prusoff
equation [36]:
Ki ¼
IC50
1þ LO
KD
LO−labelled ligand concentration, KD−dissociation constant of labelled ligand
In a case of functional studies IC50 and EC50 were determined by nonlinear regression anal-
ysis using GraphPad Prism 5.0 software.
Results
The affinity of HBK-14 and HBK-15 for serotonergic 5-HT2A, SERT,
adrenergic α1, α2 and β1 and dopaminergic D2 receptors
HBK-14 showed a high affinity for adrenergic α1 receptors, a moderate affinity for serotonergic
5-HT2A and dopaminergic D2 receptors, and a very low affinity for SERT. It had no affinity for
adrenergic α2 and β1 receptors (Table 1).
HBK-15 showed a high affinity for adrenergic α1 and dopaminergic D2 receptors, a moder-
ate affinity for serotonergic 5-HT2A and SERT, and no affinity for adrenergic α2 and β1 recep-
tors (Table 1).
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The intrinsic activity of HBK-14 and HBK-15 towards serotonergic
5-HT1A and 5-HT7 receptors
The intrinsic activity studies revealed activity of HBK-14 and HBK-15 at the target receptors
and showed antagonist properties; however, their activity was weaker than that of reference
antagonists, i.e. WAY-100635 (9-30-fold) and SB-269970 (51-147-fold) (Table 2).
Antidepressant-like activity of studied compounds in the FST in mice
Fig 2A shows that HBK-14 (2.5 and 5 mg/kg) significantly decreased immobility time of mice
(by 30% and 31%, respectively) [F(3,36) = 5.385, P = 0.0036]. HBK-15 (1.25, 2.5 and 5 mg/kg)
significantly and dose-dependently reduced immobility time (by 40%, 42% and 46%, respec-
tively) [F(4,45) = 7.897, P<0.0001] detected in FST in mice (Fig 2B). Imipramine (5 mg/kg) and
escitalopram (2.5 mg/kg), given as reference drugs, decreased immobility in mice (by 50% [F
(2,27) = 10.60, P = 0.0004] and 42% (F(2,27) = 4.177, P = 0.0263), respectively) (Fig 2C and 2D).
Table 1. The affinity for serotonergic, adrenergic and dopaminergic receptors and serotonin transporter (SERT).
Compound Serotonergic Ki [nM] Adrenergic Ki [nM] Dopaminergic Ki [nM]
5-HT2A SERT α1 α2 β1 D2
HBK-14 264 3500 23 n.a. n.a. 219
HBK-15 109 529 13 n.a. n.a. 54
Mianserin 2 — — — — —
Escitalopram — 2 — — — —
Phentolamine — — 9 — — —
Clonidine — — — 3 — —
Propranolol — — — — 8 —
Haloperidol — — — — — 1
Inhibition constants (Ki) were calculated according to the equation of Cheng and Prusoff [36].
n.a.–compound did not bind to receptor at 10-5M, SERT–serotonin transporter.
doi:10.1371/journal.pone.0142499.t001
Table 2. Functional data for the serotonergic 5-HT1A and 5-HT7 receptors.
Receptor Treatment Agonist mode Antagonist mode
Emax % pEC50 IC50 nM Kb nM
5-HT1A WAY-100635 n.c. n.c. 2.1 n.d.
Serotonin 100 6.5 n.c. n.c.
HBK-14 6 n.c. 64 49
HBK-15 8 n.c. 19 15
5-HT7 Serotonin 100 8.3 n.c. n.c.
SB 269970 4 n.c. 1.5 0.5
HBK-14 19 n.c. 77 24
HBK-15 0 n.c. 220 69
Data are expressed as the mean of two independent experiments in duplicate. Emax—the maximum possible effect, pEC50—the logarithm of concentration
of a compound where 50% of its maximal effect was observed; IC50 - (the half maximal inhibitory concentration) the concentration of a compound
producing 50% inhibition of maximal effect; Kb—the equilibrium dissociation constant of a competitive antagonist determined using of the Cheng-Prusoff
equation [37]
n.c.—noncalculable
n.d.–not determined.
doi:10.1371/journal.pone.0142499.t002
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Antidepressant-like activity of studied compounds in the FST in rats
As demonstrated in Fig 3A, HBK-14 (5 mg/kg), compared with vehicle-treatment, significantly
decreased immobility time (by 38%) [F(3,28) = 7.147, P = 0.0010], and increased swimming
behaviour by 185% [F(3,28) = 4.146, P = 0.0010] in the rat FST. The compound showed no sig-
nificant effect on the duration of climbing [F(3,28) = 2.439, P = 0.0854].
HBK-15 (1.25 and 2.5 mg/kg), compared with a control group, significantly decreased
immobility time (by 30% and 38%, respectively) [F(4,35) = 4.375, P = 0.0057], and increased
the time of swimming (by 166% and 191%, respectively) [F(4,35) = 5.422, P = 0.0017]. The
tested compound had no significant influence on climbing [F(4,35) = 0.5547, P = 0.6969] in
the FST in rats (Fig 3B).
Imipramine (10 mg/kg) significantly decreased immobility time (by 51%) [F(2,21) = 13.64,
P = 0.0002] and increased climbing behaviour (by 163%) [F(2,21) = 9.872, P = 0.0009] in rats
in the FST. The reference drug had no significant effect on the duration of swimming [F(2,21)
= 1.056, P = 0.3656] (Fig 3C).
Fig 2. Antidepressant-like activity of HBK-14, HBK-15, imipramine and escitalopram in the FST in mice.HBK-14, HBK-15, imipramine and
escitalopram were administered intraperitoneally 30 min before the test. The control groups received 0.9% NaCl. Statistical analysis: one-way ANOVA
(Newman-Keuls post hoc) *P<0.05, **P<0.01, ***P<0.001, vs respective control group; n = 10 mice per group.
doi:10.1371/journal.pone.0142499.g002
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Escitalopram (30 mg/kg), compared with a control group, significantly decreased immobil-
ity time (by 48%) [F(2,21) = 9.516, P = 0.0011] and increased swimming (by 171%) [F(2,21) =
12.35 P = 0.0003], with no influence on climbing behaviour [F(2,21) = 1.008, P = 0.3818] of
rats in FST (Fig 3D).
The influence of HBK-14 and HBK-15 on locomotor activity in mice
Neither HBK-14 nor HBK-15 influenced locomotor activity of mice in 1-min session
[F(3,36) = 0.2263, P = 0.8775, F(3,36) = 0.7642, P = 0.5216, respectively] and in 4-min session
[F(3,36) = 1.374, P = 0.2663, F(4,45) = 0.7444, P = 0.5668, respectively] (Table 3).
The influence on exploratory activity of studied compounds in rats
As shown in Table 4 there was no significant effect of HBK-14 (2.5 and 5mg/kg) on the total
number of open-arm entries and distance travelled in the EPM apparatus [F(3,27) = 2.080,
P = 0.1264, F (3,27) = 2.660, P = 0.0683, respectively]. HBK-15 at both doses had no effect on the
parameters measured [F(2,19) = 0.0205, P = 0.9798 –the total number of arm entries, F(2,19) =
2.400, P = 0.1177 –total distance travelled]. Similarly, diazepam (1.25 and 2.5 mg/kg) did not
influence the total number of arm entries and distance travelled by rats [F(2,22) = 0.4425,
P = 0.6480, F(2,22) = 0.0425, P = 0.9585, respectively] (Table 4).
The effect of joint administration of sub-effective doses of studied
compounds and fluoxetine, reboxetine or bupropion in the FST in mice
Fig 4 shows that all antidepressants given alone, i.e. fluoxetine (10 mg/kg), reboxetine (5 mg/kg)
and bupropion (2.5 mg/kg) did not affect the immobility time of mice in FST. Similarly, none of
Fig 3. The effect on immobility, swimming and climbing behaviours of HBK-14, HBK-15, imipramine and escitalopram in the FST in rats.HBK-14,
HBK-15, imipramine and escitalopram were administered intraperitoneally 30 min before the experiment. The control groups received 0.9% NaCl (vehicle).
Statistical analysis: one-way ANOVA (Newman-Keuls post hoc) *P<0.05, **P<0.01, ***P<0.001 vs respective control group; n = 8 rats per group.
doi:10.1371/journal.pone.0142499.g003
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tested compounds (HBK-14 1.25 mg/kg and HBK-15 0.625 mg/kg) administered alone affected
the mouse immobility (Fig 4). The joint administration of HBK-14 (1.25 mg/kg) and fluoxetine
(10 mg/kg) significantly decreased the immobility time (by 32%) (Fig 4A). Two-way ANOVA
presents a significant interaction between HBK-14 and fluoxetine [F(1,36) = 8.905, P = 0.0051].
Similarly, HBK-15 (0.625 mg/kg) co-administered with fluoxetine (10 mg/kg) caused a signifi-
cant reduction (by 43%) of immobility (Fig 4B). Two-way ANOVA presents a significant interac-
tion between HBK-15 and fluoxetine [F(1,36) = 4.322, P = 0.0448].
Co-administration of HBK-14 (1.25 mg/kg) with reboxetine (5 mg/kg) had no effect on
immobility time measured in the FST (Fig 4C). Two-way ANOVA demonstrates no interaction
between HBK-14 and reboxetine [F(1,36) = 0.2838, P = 0.5975]. Similarly, the joint administra-
tion of HBK-15 (0.625 mg/kg) and reboxetine (5 mg/kg), as well as both compounds injected
alone did not cause any changes in the immobility (Fig 4D). Two-way ANOVA demonstrates
no interaction between HBK-15 and reboxetine [F(1,36) = 0.2511, P = 0.7328].
Table 4. Effects of HBK-14, HBK-15 and diazepam on exploratory activity in the elevated plus maze
test in rats.
Treatment Dose Total arm entries ± SEM Total distance
travelled ± SEM (m)
(mg/kg)
Vehicle - 19.0 ± 0.2 27.3 ± 2.3
HBK-14 1.25 23.0 ± 4.7 36.1 ± 1.8
2.5 20.7 ± 5.1 30.0 ± 5.8
5 34.8 ± 4.6 39.1 ± 0.9
Vehicle - 17.1 ± 3.2 30.9 ± 2.8
HBK-15 2.5 18.2 ± 7.1 36.3 ± 1.0
5 16.8 ± 3.8 30.9 ± 2.2
Vehicle - 11.3 ± 2.9 28.5 ± 2.7
Diazepam 1.25 15.8 ± 4.1 29.1 ± 3.1
2.5 17.0 ± 4.0 31.9 ± 6.0
HBK-14, HBK-15 and diazepam were administered intraperitoneally 30 min before the test. Statistical
analysis: one-way ANOVA (Newman–Keuls post hoc); n = 7–8 rats per group
doi:10.1371/journal.pone.0142499.t004
Table 3. The influence of HBK-14 and HBK-15 on locomotor activity in 1-min and 4-min session in mice.
Treatment Dose (mg/kg) Number of crossings ± SEM
1 min 4 min
Vehicle - 104 ± 6 416 ± 57
HBK-14 1.25 93 ± 10 488 ± 58
2.5 95 ± 14 542 ± 35
5 98 ± 9 424 ± 48
Vehicle - 98 ± 11 510 ± 62
HBK-15 0.625 - 531 ± 52
1.25 108 ± 9 459 ± 43
2.5 98 ± 10 411 ± 68
5 103 ± 10 442 ± 58
HBK-14 and HBK-15 were injected intraperitoneally 30 min before the test. Vehicle-treated groups received 0.9% NaCl. Statistical analysis: one-way
ANOVA (Newman-Keuls post hoc); n = 10 mice per group.
doi:10.1371/journal.pone.0142499.t003
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Fig 4. The effect of joint administration of sub-effective doses of studied compounds and fluoxetine, reboxetine or bupropion in the FST in mice.
HBK-14, HBK-15, fluoxetine, reboxetine and bupropion were administered intraperitoneally 30 min before the test. The control groups received 0.9% NaCl.
The doses (mg/kg) are indicated in brackets. Statistical analysis: two-way ANOVA (Bonferroni post hoc) ***P<0.001, ****P<0.0001 vs respective control
group receiving 0.9% NaCl; n = 10 mice per group.
doi:10.1371/journal.pone.0142499.g004
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Combined administration of HBK-14 (1.25 mg/kg) and bupropion (2.5 mg/kg) did not
influence the immobility time in the FST (Fig 4E). Two-way ANOVA shows no interaction
between HBK-14 and bupropion [F(1,36) = 0.1551, P = 0.6960]. Similarly, HBK-15 (0.625 mg/
kg) given jointly with bupropion (2.5 mg/kg) did not influence immobility time of mice (Fig
4F). Two-way ANOVA shows and no interaction between HBK-15 and bupropion [F(1,36) =
0.0497 P = 0. 8248].
The effect of pretreatment with pCPA or WAY-100635 on
antidepressant-like activity of studied compounds in the FST in mice
HBK-14 (2.5 mg/kg) significantly reduced immobility (by 25%) in the FST in mice, whereas
3-day treatment with pCPA (200 mg/kg) did not influence immobility but antagonized the
activity of HBK-14 in this test (Fig 5A). Two-way ANOVA demonstrates a significant interac-
tion between HBK-14 and pCPA [F(1,36) = 8.312, P = 0.0066].
HBK-15 (1.25 mg/kg) significantly reduced immobility (by 22%) in the FST in mice,
whereas 3-day treatment with pCPA (200 mg/kg) did not influence immobility time; however,
Fig 5. The effect of pretreatment with pCPA orWAY-100635 on antidepressant-like activity of HBK-14 and HBK-15 in the FST in mice. p-
Chlorophenylalanine (pCPA) was injected intraperitoneally (i.p.) once daily for 3 consecutive days, and 24 h after the last injection and 30 min before the test
mice received (i.p.) either the studied compound or 0.9% NaCl. WAY-100635 was injected subcutaneously 15 min before the studied compounds. The doses
(mg/kg) are indicated in brackets. Statistical analysis: two-way ANOVA (Bonferroni post hoc) *P<0.05, **P<0.01 vs respective control group receiving 0.9%
NaCl, #P<0.05, ##P<0.01 vs respective group receiving the studied compound; n = 10 mice per group.
doi:10.1371/journal.pone.0142499.g005
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it antagonized the antidepressant activity of HBK-15 in this test (Fig 5B). Two-way ANOVA
demonstrates a significant interaction between HBK-15 and pCPA [F(1,36) = 7.208,
P = 0.0109].
Administration of WAY-100635 (0.1 mg/kg) had no effect on the duration of immobility
time by itself (Figs 5C and 4D). However, it completely antagonized the antidepressant effect
elicited by HBK-14 in this test. Two-way ANOVA shows a significant interaction between
HBK-14 and WAY-100635 [F(1,36) = 9.519, P = 0.0039]. Similarly, administration of WAY-
100635 (0.1 mg/kg) completely antagonized the effect evoked by HBK-15 in FST. Two-way
ANOVA shows a significant interaction between HBK-15 and WAY-100635 [F(1,36) = 7.443,
P = 0.0098].
The influence of joint administration of HBK-14 and HBK-15 with
fluoxetine, bupropion, reboxetine, pCPA or WAY-100635 on locomotor
activity in mice
The treatment with HBK-14, fluoxetine or their combination had no influence on locomotor
activity of mice (Table 5). Two-way ANOVA shows no significant interaction between HBK-
Table 5. The effect of HBK-14 and HBK-15 given alone or in combination with fluoxetine, reboxetine
or bupropion on locomotor activity in mice.
Treatment Number of crossings ± SEM
Vehicle 422 ± 50
HBK-14 (1.25) 511 ± 16
fluoxetine (10) 488 ± 14
HBK-14 (1.25) + fluoxetine (10) 427 ± 58
Vehicle 410 ± 47
HBK-15 (0.625) 477 ± 47
fluoxetine (10) 393 ± 41
HBK-15 (0.625) + fluoxetine (10) 494 ± 46
Vehicle 495 ± 41
HBK-14 (1.25) 477 ± 47
reboxetine (5) 393 ± 41
HBK-14 (1.25) + reboxetine (5) 494 ± 46
Vehicle 464 ± 39
HBK-15 (0.625) 399 ± 61
reboxetine (5) 366 ± 37
HBK-15 (0.625) + reboxetine (5) 365 ± 58
Vehicle 443 ± 61
HBK-14 (1.25) 356 ± 39
bupropion (2.5) 418 ± 40
HBK-14 (1.25) + bupropion (2.5) 482 ± 23
Vehicle 406 ± 37
HBK-15 (0.625) 349 ± 49
bupropion (2.5) 409 ± 44
HBK-15 (0.625) + bupropion (2.5) 343 ± 43
Fluoxetine, reboxetine, bupropion, HBK-14 and HBK-15 were administered intraperitoneally 30 min before
the test. Vehicle-treated groups received 0.9% NaCl. The doses (mg/kg) are indicated in brackets.
Statistical analysis: two-way ANOVA (Bonferroni post hoc); n = 10 mice per group.
doi:10.1371/journal.pone.0142499.t005
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15 and fluoxetine [F(1,36) = 3.535, P = 0.0682]. The joint administration of HBK-15 and fluox-
etine, as well as both compounds given alone, did not influence locomotor activity of mice
(Table 5). Two-way ANOVA shows no significant interaction between HBK-15 and fluoxetine
[F(1,36) = 0.1425, P = 0.7080].
The treatment with HBK-14, reboxetine or their combination had no influence on locomo-
tor activity of mice (Table 5). Two-way ANOVA shows no significant interaction between
HBK-14 and reboxetine [F(1,36) = 1.836, P = 0.1838]. The joint administration of HBK-15 and
reboxetine, as well as both compounds given alone, did not influence locomotor activity of
mice (Table 5). Two-way ANOVA shows no significant interaction between HBK-15 and
reboxetine [F(1,36) = 0.4307, P = 0.5158].
The treatment with HBK-14, bupropion or their combination had no influence on locomo-
tor activity of mice (Table 5). Two-way ANOVA shows no significant interaction between
HBK-14 and bupropion [F(1,36) = 0.3536, P = 0.5558]. The joint administration of HBK-15
and bupropion, as well as both compounds given alone, did not influence locomotor activity of
mice (Table 5). Two-way ANOVA shows no significant interaction between HBK-15 and
bupropion [F(1,36) = 0.0103, P = 0.9195].
HBK-14 (2.5 mg/kg), pCPA (200 mg) and their combination did not influence locomotor
activity of mice in 1 min session (Table 6). Two-way ANOVA shows no significant interaction
between HBK-14 and pCPA [F(1,36) = 0.4090, P = 0.5265]. Analogously, neither HBK-14 (2.5
Table 6. The effect of the pretreatment with pCPA or WAY-100635 on locomotor activity evoked by
HBK-14 or HBK-15 in 1-min and 4-min session in mice.
Treatment Number of crossings ± SEM
1 min 4 min
Vehicle 92 ± 11 400 ± 38
HBK-14 (2.5) 105 ± 12 344 ± 46
pCPA (200) 99 ± 11 370 ± 27
HBK-14 (2.5) + pCPA (200) 98 ± 10 350 ± 44
Vehicle 103 ± 13 380 ± 42
HBK-15 (2.5) 93 ± 14 356 ± 41
pCPA (200) 88 ± 11 408 ± 20
HBK-15 (2.5) + pCPA (200) 88 ± 10 391 ± 30
Vehicle 102 ± 8 423 ± 38
HBK-14 (2.5) 99 ± 9 363 ± 42
WAY-100635 (0.1) 95 ± 11 402 ± 36
HBK-14 (2.5) + WAY-100635 (0.1) 101 ± 6 460 ± 55
Vehicle 117 ± 8 434 ± 58
HBK-15 (2.5a/1.25b) 99 ± 7 360 ± 49
WAY-100635 (0.1) 107 ± 12 454 ± 65
HBK-15 (2.5a/1.25b) + WAY-100635 (0.1) 100 ± 9 441 ± 50
p-Chlorophenylalanine (pCPA) was injected intraperitoneally (i.p.) once daily for 3 consecutive days, and
24 h after the last injection and 30 min before the test mice received (i.p.) either the studied compound or
0.9% NaCl. WAY-100635 was injected subcutaneously 15 min before the studied compounds. The doses
(mg/kg) are indicated in brackets. Statistical analysis: two-way ANOVA (Bonferroni post hoc); n = 10 mice
per group
a 1-min session
b 4-min session.
doi:10.1371/journal.pone.0142499.t006
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mg/kg), pCPA (200 mg) nor their combination influenced locomotor activity of mice in 4 min
session (Table 6). Two-way ANOVA shows no significant interaction between HBK-14 and
pCPA [F(1,36) = 0.3062, P = 0.5834].
HBK-15 (2.5 mg/kg), pCPA (200 mg) or their combination did not influence locomotor
activity of mice in 1 min session (Table 6). Two-way ANOVA shows no significant interaction
between HBK-15 and pCPA [F(1,36) = 0.1899, P = 0.6656]. Similarly, HBK-15 (2.5 mg/kg),
pCPA (200 mg) or their combination did not influence locomotor activity of mice in 4 min ses-
sion (Table 6). Two-way ANOVA shows no significant interaction between HBK-15 and
pCPA [F(1,36) = 0.0101, P = 0.9199].
The treatment with WAY-100635 (0.1 mg/kg), HBK-14 (2.5 mg/kg) and both compounds
administered jointly did not influence locomotor activity of mice in 1-min session (Table 6).
Two-way ANOVA shows no significant interaction between HBK-14 and WAY-100635 [F
(1,36) = 0.3114, P = 0. 5803]. Similarly, the administration of WAY-100635 (0.1 mg/kg), HBK-
14 (2.5 mg/kg) and both compounds jointly did not influence locomotor activity of mice in
4-min session (Table 6). Two-way ANOVA shows no significant interaction between HBK-14
andWAY-100635 [F(1,36) = 1.890, P = 0.1777].
The injection of WAY-100635 (0.1 mg/kg), HBK-15 (2.5 mg/kg) and both compounds
jointly did not influence locomotor activity of mice in 1-min session (Table 6). Two-way
ANOVA shows no significant interaction between HBK-15 and WAY-100635 [F(1,36) =
0.3208, P = 0.5746]. Similarly, the treatment with WAY-100635 (0.1 mg/kg), HBK-15 (1.25
mg/kg) and both compounds administered jointly did not influence locomotor activity of mice
in 4-min session (Table 6). Two-way ANOVA shows no significant interaction between HBK-
15 andWAY-100635 [F(1,36) = 0.3020, P = 0.5860].
Anxiolytic-like activity of studied compounds in the four-plate test in mice
Fig 6A shows that HBK-14 (2.5 and 5 mg/kg) significantly and dose-dependently increased the
number of punished crossings (by 68% and 87%, respectively) [F(3,36) = 9.867, P<0.0001], in
the four-plate test in mice. HBK-15 (2.5 and 5 mg/kg) also increased the parameter measured
(by 52% and 88%, respectively) in that test acting in the dose-dependent manner (F(3,36) =
8.396, P = 0.0002) (Fig 6B). Diazepam (1.25 and 2.5 mg/kg), given as a reference anxiolytic,
increased the number of punished crossings (by 62% and 73%, respectively) in the four-plate
test in mice [F(3,36) = 12.14, P<0.0001] (Fig 6C).
Anxiolytic-like activity of studied compounds in the EPM in rats
As demonstrated in Fig 7A HBK-14 (2.5 mg/kg) significantly increased the percentage of time
spent in the open arms (by 591%) [F(3,27) = 9.238, P = 0.0002], as well as the percentage of
Fig 6. The anxiolytic-like activity of HBK-14, HBK-15 and diazepam in the four-plate test in mice.HBK-14, HBK-15 and diazepam were administered
intraperitoneally 30 min before the experiment. The control groups received 0.9% NaCl. Statistical analysis: one-way ANOVA (Newman-Keuls post hoc)
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs respective control group; n = 10 mice per group.
doi:10.1371/journal.pone.0142499.g006
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open-arm entries (by 90%) [F(3,27) = 3.543, P = 0.0277]. HBK-15 (5 mg/kg) showed a similar
but weaker effect, increasing the percentage of time spent in the open arms (by 198%) [F(2,19)
= 4.351, P = 0.027] and percentage of open-arm entries (by 89%) (F (2,19) = 6.692, P = 0.0063)
(Fig 7B). Diazepam (2.5 mg/kg) significantly increased the percentage of both parameters mea-
sured in EPM, i.e. time spent in the open arms (by 672%) [F(2,20) = 8.474, P = 0.0022] and
open-arm entries (by 131%) [F(2,20) = 6.249, P = 0.0078] (Fig 7C).
The effect of pretreatment with pCPA or WAY-100635 on anxiolytic-like
activity of studied compounds in the four-plate test in mice
HBK-14 (2.5 mg/kg) increased the number of punished crossings (by 105%) in the four-plate
test (Fig 8A). 3-day treatment with pCPA (200 mg/kg) had no effect on the number of pun-
ished crossings, but it completely antagonized the anxiolytic effect elicited by HBK-14 in this
test. Two-way ANOVA shows a significant interaction between HBK-14 and pCPA [F(1,36) =
11.27, P = 0.0019].
Compared with vehicle treatment, HBK-15 (2.5 mg/kg) significantly increased (by 109%)
the number of punished crossings in mice (Fig 8B). 3-day treatment with pCPA (200 mg/kg)
showed no effect on the number of punished crossings in the four-plate test; however, it
completely antagonized the effect evoked by HBK-15 in this test. Two-way ANOVA shows a
significant interaction between HBK-15 and pCPA [F(1,36) = 7.138, P = 0.0113].
HBK-15 (2.5 mg/kg) increased the number of punished crossings (by 82%) in the four-plate
test. Administration of WAY-100635 (0.1 mg/kg) had no effect on the number of punished
crossings by itself, but it completely antagonized the effect elicited by HBK-14 in this test.
Two-way ANOVA shows a significant interaction between HBK-14 andWAY-10635
[F(1,36) = 4.213, P = 0.0474] (Fig 8C).
Compared with vehicle treatment, HBK-15 (2.5 mg/kg) significantly increased (by 111%)
the number of punished crossings in mice (Fig 8D). Administration of WAY-100635 (0.1 mg/
kg) showed no effect on the number of punished crossings in the four-plate test; however, it
completely antagonized the effect elicited by HBK-15 in this test. Two-way ANOVA shows a
significant interaction between HBK-15 and WAY-100635 [F(1,36) = 5.505, P = 0.0246].
Discussion
Our former studies revealed that HBK-14 and HBK-15, novel 2-methoxyphenylpiperazine
derivatives, present a high affinity toward 5-HT1A receptors (Ki = 41 nM and Ki<1 nM, respec-
tively), slightly weaker one toward 5-HT7 (Ki = 156 nM and Ki = 34 nM, respectively), and no
affinity toward 5-HT6 receptors (Ki = 9967 nM and Ki = 9617 nM, respectively) [22]. As inter-
esting dual 5-HT1A/5-HT7 ligands, the studies were continued and obtained findings have
Fig 7. The influence of HBK-14, HBK-15 and diazepam on the time spent in open arms and open-arm entries in the elevated plus maze in rats.HBK-
14, HBK-15 and diazepamwere administered intraperitoneally 30 min before the experiment. The control group received 0.9% NaCl. Statistical analysis:
one-way ANOVA (Newman-Keuls post hoc) *P<0.05, **P<0.01, ***P<0.001 vs respective control group; n = 7–8 rats per group.
doi:10.1371/journal.pone.0142499.g007
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broadened their in vitro profile indicating a high interaction of HBK-14 and HBK-15 with
α1-adrenoceptors and a weaker one with 5-HT2A and D2 receptors. Furthermore, both com-
pounds have low affinity for SERT and no affinity for adrenergic α2 and β1 receptors (Table 1).
The results obtained in functional in vitro assays present both compounds tested as antagonists
of serotonergic 5-HT1A and 5-HT7 receptors; however, their activity did not reach as high
antagonist level as that of reference WAY-100635 and SB-269970, respectively (Table 2).
It is well known that 5-HT7 receptor antagonists possess antidepressant- and anxiolytic-like
properties present in various animal models [29,38]. Furthermore, in depressed individuals the
blockade of 5-HT1A autoreceptors may be beneficial, since in these patients an over-expression
of presynaptic 5-HT1A receptors has been reported [39].
For preliminary evaluation of antidepressant-like properties of studied compounds, we used
the FST in mice. This test is a reliable tool for predicting the therapeutic potential of new com-
pounds, in which a broad spectrum of antidepressants show activity, decreasing the time of
behavioural despair of rodents [40]. We demonstrate that HBK-14 and HBK-15 produced
dose-dependent antidepressant-like effects in that test, and the effect, in case of HBK-15, was
Fig 8. The effect of pretreatment with pCPA orWAY-100635 on anxiolytic-like activity of HBK-14 and HBK-15 in the four-plate test in mice. p-
Chlorophenylalanine (pCPA) was injected intraperitoneally (i.p.) once daily for 3 consecutive days, and 24 h after the last injection and 30 min before the test
mice received (i.p.) either the studied compound or 0.9% NaCl. WAY-100635 was injected subcutaneously 15 min before the studied compounds. The doses
(mg/kg) are indicated in brackets. Statistical analysis: two-way ANOVA (Bonferroni post hoc) **P<0.01, ***P<0.001 vs respective control group receiving
0.9% NaCl, #P<0.05, ##P<0.01 vs respective group receiving the studied compound; n = 10 mice per group.
doi:10.1371/journal.pone.0142499.g008
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even stronger than that of escitalopram and imipramine (Fig 2). None of the compounds tested
affected locomotor activity of mice after administration at antidepressant-like doses (Table 3),
thus we can conclude that observed antidepressant-like effects of all tested compounds are spe-
cific. Such antidepressant-like properties of HBK-14 and HBK-15 were also previously
observed in mice in another screening test used, i.e. tail suspension test. So our present findings
additionally endorse their antidepressant-like activity. In order to examine a possible mecha-
nism of antidepressant-like action of the studied compounds in the FST in mice, we investi-
gated their effect on the action of several antidepressants with diverse pharmacological profiles,
administered at sub-effective doses. Interaction studies with conventional antidepressants are
essential for conclusive assessment of antidepressant potential of a new compound [41], and
may help to determine which system plays a role in the mechanism of its action [42]. Our stud-
ies revealed synergistic effect after joint administration of sub-effective doses of HBK-14 and
HBK-15 with fluoxetine, but the combined treatment of both new compounds with reboxetine
or bupropion did not cause any significant changes in immobility time duration (Fig 4). Since
neither the studied compounds given alone nor their combinations with fluoxetine caused any
changes in locomotor activity of mice (Table 3), the observed antidepressant-like effect was
specific. Taking into account the above results, we can conclude that the antidepressant-like
effects of HBK-14 and HBK-15 are most likely due to the interaction with the serotonergic sys-
tem. To confirm its possible contribution in the antidepressant-like activity of the studied com-
pounds, we depleted serotonin levels in mice by pretreatment with pCPA, a selective inhibitor
of the rate-limiting enzyme in the biosynthesis of serotonin, tryptophan hydroxylase [43].
Studies have shown that the 3-day treatment with pCPA (200 mg/kg), significantly reduces the
levels of serotonin in cortex, diencephalon, midbrain and pons & medulla in mice by around
30%, 35%, 24% and 34%, respectively [44]. The pretreatment with pCPA completely antago-
nised the antidepressant-like effect of HBK-14 and HBK-15 without changing the baseline
activity of mice (Fig 5A and 5B, Table 6). This confirms that antidepressant-like activity of
both studied compounds is conditioned by the integrity of serotonergic neurons. Such a con-
cept is in line with data showing high affinity of both HBK-14 and HBK-15 toward 5-HT1A
receptors, which have been classified, as pre- and postsynaptic. The significance of 5-HT1A
receptor-mediated signalling in antidepressant-like effects observed in behavioural animal
studies has been demonstrated [45]. To explore a role of 5-HT1A receptors in the antidepres-
sant-like effect of studied compounds, we pretreated mice with a selective 5HT1A receptor
antagonist—WAY-100635, since this compound, given alone, did not evoke any effect in the
FST in mice (Fig 4C and 4D). Interestingly, the pretreatment with WAY-100635 significantly
reduced antidepressant-like activity of both compounds in the FST (Fig 5C and 5D). As neither
the studied compounds nor their combinations with WAY-100635 caused any changes in loco-
motor activity in mice, the observed antidepressant-like activity was specific (Table 6). Hence,
it may be concluded that the activation of 5-HT1A receptors is essential for the antidepressant-
like effect of HBK-14 and HBK-15.
In the modified FST in rats both compounds showed antidepressant-like activity (Fig 3).
The effect of HBK-14 was comparable to imipramine and stronger than escitalopram, and the
activity of HBK-15 was stronger than the effect elicited by both studied reference drugs (Fig 3).
It is notable that HBK-15 produced a U-shaped dose-response effect in rat FST. This effect is
common for antidepressants with various mechanisms of action. It may be a result of some
non-specific activity of the compound, which prevents a further decrease in immobility time
[46]. Since none of the compounds influenced the exploratory activity of rats in the plus maze,
the observed antidepressant-like activity was specific (Table 4). Similarly to escitalopram, both
studied 2-methoxyphenylpiperazine derivatives significantly increased the time of swimming
and did not influence climbing behaviours in the modified FST in rats (Fig 3). This pattern of
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rats' responding has been regarded as indicative of an enhanced serotonergic transmission and
attributed to SSRIs action [33,47]. Thus, this increase in swimming yet not climbing behaviour
indicates the serotonergic rather than the noradrenergic pathway's contribution to the antide-
pressant-like action of HBK-14 and HBK-15 in the FST in rats.
For preliminary evaluation of anxiolytic-like properties of investigated compounds, the
four-plate test in mice was performed. This test is based on conflict situation, in which electric
shock inhibits the mouse’s exploratory activity. Anxiolytics increase the number of punished
crossings. Both HBK-14 and HBK-15 showed dose-dependent anxiolytic-like activity in the
four-plate test in mice, but their effect was not as strong as the effect of diazepam (Fig 6). As
neither HBK-14 nor HBK-15 affected locomotor activity in mice at anxiolytic doses (Table 3),
the observed effect is be specific.
The function of serotonergic system, and especially 5-HT1A receptors, is altered in patients
with anxiety disorders [48]. Besides, 5-HT1A receptors play a significant role in anxiolytic-like
effects [49]. Taking it into account, we decided to examine the role of serotonergic system in
mechanism of anxiolytic action of HBK-14 and HBK-15. In order to do that, we pretreated
mice with pCPA for 3 consecutive days. The pretreatment with pCPA completely antagonised
the anxiolytic-like effect of the studied compounds without changing the baseline activity of
mice (Fig 8A and 8B, Table 6). This confirmed the integrity of serotonergic neurons in anxio-
lytic-like activity of HBK-14 and HBK-15. Moreover, the pretreatment with WAY-100635,
which given alone did not evoke any effect in the mouse four-plate test, (Fig 7C and 7D), signif-
icantly reduced anxiolytic-like effects of both compounds in the four-plate test (Fig 8C and
8D). Since neither the studied compounds nor their combinations with WAY-100635 caused
any changes in locomotor activity in mice, the observed anxiolytic-like activity was specific
(Table 6). It may be concluded, though, that the activation of 5HT1A receptors is essential for
the appearance of anxiolytic-like effect of HBK-14 and HBK-15.
To confirm the anxiolytic-like properties of studied compounds, we performed EPM test.
The test is based on rodents' aversion of open spaces, which results in avoiding of open areas
by confining movements to enclosed spaces. Anxiolytics increase the open arm exploration
time and open arm entries. In this model, both compounds produced an anxiolytic-like effect
(Fig 7). We present that HBK-14 and HBK-15 increased the percentage of time spent in open
arms and the percentage of open arms entries (Fig 7). The effect of HBK-14 was comparable to
diazepam, and stronger than that of HBK-15. Our findings show that HBK-14 presents anxio-
lytic-like properties at one medium dose only. This is the common phenomenon with com-
pounds with anxiolytic-like activity [50] and is difficult to explain on this stage of
experimentation. As none of the compounds at anxiolytic-like doses affected the total number
of arm visits and the distance travelled by rats, their anxiolytic-like action cannot be explained
by competing behaviours, such as enhancement of locomotor activity (Table 4).
Conclusions
In conclusion, in the present study we have demonstrated that HBK-14 and HBK-15 are weak
serotonergic 5-HT1A and 5-HT7 receptor antagonists, showing potent and specific antidepres-
sant- and anxiolytic-like properties in various rodents’models. Among the two, HBK-15 pos-
sesses stronger antidepressant-like activity both in mice and rats. In contrast, HBK-14 shows
stronger anxiolytic-like activity especially in rats. Both compounds require intact serotonergic
system and 5-HT1A receptors’ activation, to display antidepressant- and anxiolytic-like effects.
The promising results obtained so far should be corroborated by further studies conducted
using other animal models to determine full pharmacological profile of the studied 2-methoxy-
phenylpiperazine derivatives.
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